search
Back to results

Clinical Variability in Marfan Syndrome (Variarfan)

Primary Purpose

Marfan Syndrome

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
skin punch biopsy and molecular biology
fibroblast culture and molecular biology
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Marfan Syndrome focused on measuring Marfan syndrome, Variability, Fibrillin 1, clinical expression

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Man or woman > 18 years old
  • With a mutation in FBN1 gene
  • Has signed an informed consent form

Exclusion Criteria:

-No affiliated to a Healthcare System.

Sites / Locations

  • Centre de Reference Maladie de Marfan Et Apparente

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Marfan patients

control patients

Arm Description

Study participants were recruited between 11/2009 and 10/2011, among adult patients consulting in the Multidisciplinary Marfan Clinic of our University Hospital, and having a known mutation in the FBN1 gene. There, patients are evaluated by geneticists, rheumatologists, cardiologists, and ophthalmologists. Systematic slit-lamp examination, cardiac ultrasonography, and radiological investigations are also performed. A skin punch biopsy was used to establish a fibroblast cell culture. We determined mRNA levels for FBN1 and compared it to the clinical involvement.

Fibroblasts were obtained from non Marfan patients (cell bank). We determineed mRNA level for FBN1 for each allele.

Outcomes

Primary Outcome Measures

FBN1 expression level
Evaluation in Marfan patients, of FBN1 expression level (non-mutated or mutated allele) compared to the clinical expression of the disease in idividuals

Secondary Outcome Measures

Full Information

First Posted
October 12, 2012
Last Updated
November 5, 2014
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Hospices Civils de Lyon, Banque de cellules cochin
search

1. Study Identification

Unique Protocol Identification Number
NCT01707563
Brief Title
Clinical Variability in Marfan Syndrome
Acronym
Variarfan
Official Title
Correlations' Study Between Variability of Expression in FBN1 Gene and Clinical Features in Marfan Patients.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2010
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
January 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Hospices Civils de Lyon, Banque de cellules cochin

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Marfan syndrome is an autosomal dominant connective tissue disorder caused by mutations in the fibrillin-1 gene (FBN1). Penetrance of FBN1 mutations is complete but intra and inter familial clinical expressivity is extremely variable. The underlying mechanisms for variability are not understood. An interesting mechanism is that the expression level of the wild type and/or mutated allele may play a role in the determination of variability. Principal objective: To evaluate in Marfan patients, if FBN1 expression level (non-mutated or mutated allele) modulates the clinical expression of the disease. Judgment criteria : Correlation allelic expression level-phenotype Perspectives : To search the predictive factors of severity in order to ameliorate precocity of taking care.
Detailed Description
Marfan syndrome is an autosomal dominant connective tissue disorder caused by mutations in the fibrillin-1 gene (FBN1). Penetrance of FBN1 mutations is complete but intra and inter familial clinical expressivity is extremely variable. The underlying mechanisms for variability are not understood. An interesting mechanism is that the expression level of the wild type and/or mutated allele may play a role in the determination of variability. Principal objective : To evaluate in Marfan patients, if FBN1 expression level (non-mutated or mutated allele) modulates the clinical expression of the disease in individuals from families with clinical variability (intrafamilial) and in independant probands (interfamilial). Judgment criteria : Correlation allelic expression level-phenotype Method : In Marfan patients with a FBN1 nul allele, FBN1 RNA will be extracted from a fibroblast culture. Allelic FBN1 expression level will be performed by quantitative RT-PCR and then compared with clinical evaluation. Number of subjects : 160 subjects, 45 Marfan patients in 15 independent families, 5 patients with the same mutation, 30 with a private mutation leading to a nul allele and 80 non Marfan subjects. Perspectives : To search the predictive factors of severity in order to ameliorate precocity of taking care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Marfan Syndrome
Keywords
Marfan syndrome, Variability, Fibrillin 1, clinical expression

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
160 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Marfan patients
Arm Type
Other
Arm Description
Study participants were recruited between 11/2009 and 10/2011, among adult patients consulting in the Multidisciplinary Marfan Clinic of our University Hospital, and having a known mutation in the FBN1 gene. There, patients are evaluated by geneticists, rheumatologists, cardiologists, and ophthalmologists. Systematic slit-lamp examination, cardiac ultrasonography, and radiological investigations are also performed. A skin punch biopsy was used to establish a fibroblast cell culture. We determined mRNA levels for FBN1 and compared it to the clinical involvement.
Arm Title
control patients
Arm Type
Other
Arm Description
Fibroblasts were obtained from non Marfan patients (cell bank). We determineed mRNA level for FBN1 for each allele.
Intervention Type
Procedure
Intervention Name(s)
skin punch biopsy and molecular biology
Intervention Type
Other
Intervention Name(s)
fibroblast culture and molecular biology
Primary Outcome Measure Information:
Title
FBN1 expression level
Description
Evaluation in Marfan patients, of FBN1 expression level (non-mutated or mutated allele) compared to the clinical expression of the disease in idividuals
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Man or woman > 18 years old With a mutation in FBN1 gene Has signed an informed consent form Exclusion Criteria: -No affiliated to a Healthcare System.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chantal Stheneur, PHD, MD
Organizational Affiliation
Hôpital Bichat, AP-HP
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre de Reference Maladie de Marfan Et Apparente
City
Paris
State/Province
Ile de France
ZIP/Postal Code
75018
Country
France

12. IPD Sharing Statement

Learn more about this trial

Clinical Variability in Marfan Syndrome

We'll reach out to this number within 24 hrs